January 21, 2026 - Navidence is pleased to announce the promotion of Andrew Ecob to Chief Commercial Officer (CCO), recognizing his leadership in driving growth and his deep expertise in real-world evidence and clinical research services.

Navidence, a technology company focused on defining health data and supporting researchers to perform study design in the age of data, today announced the promotion of Andrew Ecob to Chief Commercial Officer (CCO). In this expanded role, Ecob will lead Navidence’s global commercial strategy, including go-to-market, client partnerships, and revenue growth initiatives.​

Ecob previously served as Senior Vice President of Growth at Navidence, where he played a key role in accelerating adoption of the company’s tech-enabled, standards-based platform for RWE design and RWD assessment. With more than 20 years of experience in pharmaceutical development and clinical research services, he brings a strong track record of building innovative offerings and strategic client relationships.

Before joining Navidence, Ecob held senior roles across the life sciences and contract research sectors, including Head of Emerging Design Delivery, Real World Solutions at IQVIA; Vice President, Real World Evidence Strategy at Parexel; and Head of Business Development, Real World Evidence at inVentiv Health (Syneos Health). He is also the founder of AEDEA Consulting, further underscoring his leadership in advancing real-world evidence strategies for global biopharmaceutical clients. 

“As the Life Sciences field advances, our stakeholders are increasing their expectations of the evidence we generate from RWD," explains Aaron Kamauu, CEO of Navidence. “As such, we need experts who understand where RWD is best applied to clinical research needs and stakeholder requirements. Andrew is exceptional at bridging this gap, and I’m very excited for him to lead commercial and client engagement for Navidence.”

In his new role, Ecob will lead all client engagement activities and work closely with Navidence’s leadership team to deepen strategic partnerships and ensure the company’s Computable Operational Definition (CODef)–driven platform continues to address emerging regulatory, scientific, and operational needs of Navidence’s clients. 

Founded in 2022, Navidence offers AI-native technology and professional services that make it radically easier to design and deploy clinical research studies using RWD. The company’s platform develops Computable Operational Definitions (CODs), which are standardized, human and computer-readable definitions of key study elements, allowing for a bridge between clinical healthcare and research studies. This provides the consistency, precision, efficiency, and trust needed for the rigorous science demanded by regulatory agencies. 

About Navidence

Navidence is a technology company that helps healthcare and life science organizations design and assess the use of Real-World Data (RWD) in clinical research studies and clinical trials. Through its platform and Computable Operational Definitions (CODefs), Navidence enables consistent, transparent, and reproducible analysis of complex real-world data to support smarter research and better patient outcomes.